Back HIV/AIDS HIV/AIDS Topics HIV Prevention Post-exposure Prophylaxis (PEP)

AIDS 2014: Only Half of People Who Start HIV Post-exposure Prophylaxis Complete the Course

There are significant losses at each step of the post-exposure prophylaxis (PEP) "treatment cascade," according to a systematic review and meta-analysis of 97 studies presented to the 20th International AIDS Conference last month in Melbourne. The problems with uptake, adherence, and completion point to a need for a simplified approach, researchers said.

alt

Read more:

CROI 2014: Self-Reports Did Not Reflect Actual Gel or Pill Use in VOICE PrEP Trial

Self-reported adherence to daily tenofovir or Truvada pills or tenofovir vaginal gel for pre-exposure prophylaxis (PrEP) against HIV infection did not match drug levels in the body, helping to explain the lack of protection seen in the VOICE trial, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.

alt

Read more:

Raltegravir Shows Long-term Treatment Benefit, Appears Useful for Post-Exposure Prevention

The U.S. Food and Drug Administration (FDA) recently approved new product label information for raltegravir (Isentress), adding longer-term data showing that the drug remains effective for more than 3 years. In related news, researchers reported that raltegravir appears to be a good option for post-exposure prophylaxis (PEP) to prevent HIV infection.alt

Read more:

New PEP Guidelines Recommend 3-Drug ART After Occupational HIV Exposure

The U.S. Public Health Service this month released updated guidelines for post-exposure prophylaxis (PEP) after occupational exposure in healthcare settings to blood or other body fluids that may contain HIV. The new recommendations call for immediately starting a 4-week regimen containing at least 3 antiretroviral drugs.

alt

Read more:

IAS 2009: Tenofovir/emtricitabine (Truvada) plus Lopinavir/ritonavir (Kaletra) or Raltegravir (Isentress) Work Well for Post-exposure Prophylaxis

Post-exposure prophylaxis (PEP) regimens consisting of tenofovir/emtricitabine (Truvada) plus lopinavir/ritonavir (Kaletra) or raltegravir (Isentress) prevent HIV infection as well as zidovudine/lamivudine (Combivir) regimens, but with fewer side effects, according to 2 presentations at the recent 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa.

Read more: